218 related articles for article (PubMed ID: 33219901)
1. Development and Refinement of a Telehealth Intervention for Symptom Management, Distress, and Adherence to Adjuvant Endocrine Therapy after Breast Cancer.
Jacobs JM; Walsh EA; Rapoport CS; Antoni MH; Park ER; Post K; Comander A; Peppercorn J; Safren SA; Temel JS; Greer JA
J Clin Psychol Med Settings; 2021 Sep; 28(3):603-618. PubMed ID: 33219901
[TBL] [Abstract][Full Text] [Related]
2. A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.
Jacobs JM; Post K; Massad K; Horick NK; Walsh EA; Cohn J; Rapoport CS; Clara AJ; Antoni MH; Safren SA; Partridge AH; Peppercorn JM; Park ER; Temel JS; Greer JA
Cancer; 2022 Oct; 128(19):3541-3551. PubMed ID: 35924869
[TBL] [Abstract][Full Text] [Related]
3. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
[TBL] [Abstract][Full Text] [Related]
4. Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy.
Green SMC; French DP; Graham CD; Hall LH; Rousseau N; Foy R; Clark J; Parbutt C; Raine E; Gardner B; Velikova G; Moore SJL; Buxton J; ; Smith SG
BMC Health Serv Res; 2022 Aug; 22(1):1081. PubMed ID: 36002831
[TBL] [Abstract][Full Text] [Related]
5. Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial.
Walsh EA; Post K; Massad K; Horick N; Antoni MH; Penedo FJ; Safren SA; Partridge AH; Peppercorn J; Park ER; Temel JS; Greer JA; Jacobs JM
Breast Cancer Res Treat; 2024 Apr; 204(3):547-559. PubMed ID: 38231313
[TBL] [Abstract][Full Text] [Related]
6. Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).
Shelby RA; Dorfman CS; Bosworth HB; Keefe F; Sutton L; Owen L; Corsino L; Erkanli A; Reed SD; Arthur SS; Somers T; Barrett N; Huettel S; Gonzalez JM; Kimmick G
Contemp Clin Trials; 2019 Jan; 76():120-131. PubMed ID: 30472215
[TBL] [Abstract][Full Text] [Related]
7. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
[TBL] [Abstract][Full Text] [Related]
8. Study protocol for a randomised controlled feasibility trial of a virtual intervention (STRIDE) for symptom management, distress and adherence to adjuvant endocrine therapy after breast cancer.
Jacobs JM; Rapoport CS; Horenstein A; Clay M; Walsh EA; Peppercorn J; Temel JS; Greer JA
BMJ Open; 2021 Jan; 11(1):e041626. PubMed ID: 33397667
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
[TBL] [Abstract][Full Text] [Related]
10. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
[TBL] [Abstract][Full Text] [Related]
11. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?
Ekinci E; Nathoo S; Korattyil T; Vadhariya A; Zaghloul HA; Niravath PA; Abughosh SM; Trivedi MV
J Cancer Surviv; 2018 Jun; 12(3):348-356. PubMed ID: 29396760
[TBL] [Abstract][Full Text] [Related]
12. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
[TBL] [Abstract][Full Text] [Related]
13. Systematic adaptation of the adherence improving self-management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach.
Janssen AM; Dam J; Prins J; Buffart LM; de Bruin M
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13721. PubMed ID: 36263723
[TBL] [Abstract][Full Text] [Related]
14. Randomized Controlled Pilot Trial of a Low-Touch Remotely-Delivered Values Intervention to Promote Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors.
Arch JJ; Crespi CM; Levin ME; Genung SR; Nealis M; Mitchell JL; Bright EE; Albright K; Magidson JF; Stanton AL
Ann Behav Med; 2022 Aug; 56(8):856-871. PubMed ID: 35323853
[TBL] [Abstract][Full Text] [Related]
15. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
[TBL] [Abstract][Full Text] [Related]
16. Understanding pain related to adjuvant endocrine therapy after breast cancer: A qualitative report.
Walsh EA; Chabria R; Vranceanu AM; Park ER; Post K; Peppercorn J; Temel JS; Greer JA; Jacobs JM
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13723. PubMed ID: 36196499
[TBL] [Abstract][Full Text] [Related]
17. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
[TBL] [Abstract][Full Text] [Related]
18. Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients.
Woolpert KM; Schmidt JA; Ahern TP; Hjorth CF; Farkas DK; Ejlertsen B; Collin LJ; Lash TL; Cronin-Fenton DP
Breast Cancer Res; 2024 Apr; 26(1):59. PubMed ID: 38589932
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy use among Appalachian breast cancer survivors.
Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
Lee C; Check DK; Manace Brenman L; Kushi LH; Epstein MM; Neslund-Dudas C; Pawloski PA; Achacoso N; Laurent C; Fehrenbacher L; Habel LA
Breast Cancer Res Treat; 2020 Feb; 180(1):219-226. PubMed ID: 31975315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
